Show simple item record

dc.contributor.authorHigham, Claire E
dc.contributor.authorFaithfull, S
dc.date.accessioned2015-09-17T11:10:00Zen
dc.date.available2015-09-17T11:10:00Zen
dc.date.issued2015-08-11en
dc.identifier.citationBone health and pelvic radiotherapy. 2015: Clin Oncolen
dc.identifier.issn1433-2981en
dc.identifier.pmid26276560en
dc.identifier.doi10.1016/j.clon.2015.07.006en
dc.identifier.urihttp://hdl.handle.net/10541/577413en
dc.description.abstractSurvivors who have received pelvic radiotherapy make up many of the long-term cancer population, with therapies for gynaecological, bowel, bladder and prostate malignancies. Individuals who receive radiotherapy to the pelvis as part of their cancer treatment are at risk of insufficiency fractures. Symptoms of insufficiency fractures include pelvic and back pain and immobility, which can affect substantially quality of life. This constellation of symptoms can occur within 2 months of radiotherapy up to 63 months post-treatment, with a median incidence of 6-20 months. As a condition it is under reported and evidence is poor as to the contributing risk factors, causation and best management to improve the patient's bone health and mobility. As radiotherapy advances, chronic symptoms, such as insufficiency fractures, as a consequence of treatment need to be better understood and reviewed. This overview explores the current evidence for the effect of radiotherapy on bone health and insufficiency fractures and identifies what we know and where gaps in our knowledge lie. The overview concludes with the need to take seriously complaints of pelvic pain from patients after pelvic radiotherapy and to investigate and manage these symptoms more effectively. There is a clear need for definitive research in this field to provide the evidence-based guidance much needed in practice.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Clinical oncology (Royal College of Radiologists (Great Britain))en
dc.titleBone health and pelvic radiotherapy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, The Christie Hospital NHS Foundation Trust, Manchester, UKen
dc.identifier.journalClinical Oncologyen
html.description.abstractSurvivors who have received pelvic radiotherapy make up many of the long-term cancer population, with therapies for gynaecological, bowel, bladder and prostate malignancies. Individuals who receive radiotherapy to the pelvis as part of their cancer treatment are at risk of insufficiency fractures. Symptoms of insufficiency fractures include pelvic and back pain and immobility, which can affect substantially quality of life. This constellation of symptoms can occur within 2 months of radiotherapy up to 63 months post-treatment, with a median incidence of 6-20 months. As a condition it is under reported and evidence is poor as to the contributing risk factors, causation and best management to improve the patient's bone health and mobility. As radiotherapy advances, chronic symptoms, such as insufficiency fractures, as a consequence of treatment need to be better understood and reviewed. This overview explores the current evidence for the effect of radiotherapy on bone health and insufficiency fractures and identifies what we know and where gaps in our knowledge lie. The overview concludes with the need to take seriously complaints of pelvic pain from patients after pelvic radiotherapy and to investigate and manage these symptoms more effectively. There is a clear need for definitive research in this field to provide the evidence-based guidance much needed in practice.


Files in this item

This item appears in the following Collection(s)

Show simple item record